Trending...
- Innovative Ear Muff Hat Combines Warmth and Convenience in One Winter Accessory
- New Portable Toilet Drain Adapter Eliminates Manual Waste Tank Emptying
- Night Shade Introduces Smart Privacy Protection for Modern Devices
CHICAGO ~ MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA" or the "Company"), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for cancer, recently announced that it has closed its previously announced registered direct offering for the issuance and sale of an aggregate of 2,424,243 of its shares of common stock at a purchase price of $1.65 per share. In a concurrent private placement, MAIA also issued and sold unregistered warrants to purchase up to an aggregate of 2,424,243 shares of its common stock.
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. MAIA currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities.
More on illi News
The unregistered warrants have an exercise price $1.86 per share, become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by MAIA pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-273984), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 15, 2023 and declared effective by the SEC on August 23, 2023. The offering was made only by means of a prospectus supplement that forms a part of this registration statement which was filed with SEC and is available on their website located at http://www.sec.gov . Electronic copies may also be obtained by contacting H.C Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor New York NY 10022 or by phone at (212) 856-5711 or e-mail at placements@hcwco.com .
More on illi News
The offer and sale of unregistered warrants in this private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of Securities Act 1933 or Rule 506(b) Regulation D promulgated thereunder nor have they been registered under Securities Act or applicable state securities laws; therefore these unregistered warrants offered in this private placement along with underlying shares may not be reoffered or resold in United States except pursuant to an effective registration statement or an applicable exemption from registration requirements under Securities Act or such applicable state securities laws .
MAIA Biotechnology Inc., is focused on developing first-in-class drugs with novel mechanisms that are intended to improve lives people with cancer; their lead program is THIO which is being developed for treatment NSCLC patients with telomerase positive cancer cells . For more information please visit www .maiabiotech .com
H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The gross proceeds to MAIA from the offering were approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by the Company. MAIA currently intends to use the net proceeds from the offering for working capital and general corporate purposes as well as to fund research and development activities.
More on illi News
- Melzi Job Coach Launches on iOS and Android: A Privacy-First AI Career Engine Built for Execution
- Naperville Police Participate in St. Patrick's Day Traffic Safety Campaign
- New partnership bringing trauma-informed libraries to vulnerable children
- Training Lofts Launches $1,099 Unlimited Training Membership Featuring Semi-Private Coaching, Nutrition Support, and Recovery Services
- Naperville and Aurora Joint Release: North Aurora Road Closure between Pennsbury Lane & Frontenac Road Starts March 31
The unregistered warrants have an exercise price $1.86 per share, become exercisable six months following issuance and will expire five and one-half years from the date of issuance. The shares of common stock offered in the registered direct offering (but excluding the unregistered warrants offered in the concurrent private placement and the shares of common stock underlying such unregistered warrants) were offered and sold by MAIA pursuant to a "shelf" registration statement on Form S-3 (Registration No. 333-273984), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on August 15, 2023 and declared effective by the SEC on August 23, 2023. The offering was made only by means of a prospectus supplement that forms a part of this registration statement which was filed with SEC and is available on their website located at http://www.sec.gov . Electronic copies may also be obtained by contacting H.C Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor New York NY 10022 or by phone at (212) 856-5711 or e-mail at placements@hcwco.com .
More on illi News
- American Properties Realty, Inc. Leadership Attends NAHB International Builders' Show in Florida
- Mayor Brandon Johnson Announces 2nd Annual Chicago River Swim Following Historic First Year, Establishing New Civic Tradition
- $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
- Jones Software Corp Expands AI Skilling Through Microsoft Commercial Marketplace with Global Deliver
- ASI Hosts 2026 Executive Business Summit for Global Partner Community
The offer and sale of unregistered warrants in this private placement were made in a transaction not involving a public offering and have not been registered under Section 4(a)(2) of Securities Act 1933 or Rule 506(b) Regulation D promulgated thereunder nor have they been registered under Securities Act or applicable state securities laws; therefore these unregistered warrants offered in this private placement along with underlying shares may not be reoffered or resold in United States except pursuant to an effective registration statement or an applicable exemption from registration requirements under Securities Act or such applicable state securities laws .
MAIA Biotechnology Inc., is focused on developing first-in-class drugs with novel mechanisms that are intended to improve lives people with cancer; their lead program is THIO which is being developed for treatment NSCLC patients with telomerase positive cancer cells . For more information please visit www .maiabiotech .com
Filed Under: Business
0 Comments
Latest on illi News
- Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
- Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
- The Franchise King® Releases Free Guide for Nervous Buyers
- Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
- CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
- NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
- Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
- Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
- Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
- Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples
- The Friendly Music Community Unveils The Friendly Listening Room with Premier Performance by Acclai
- Matthew Sisneros Releases Raw and Unfiltered Memoir: The Devil Lost Another One — A Powerful Story of Crime, Consequence, and Redemption
- From Life to Light: Jess L. Martinez Shares a Soulful Poetry Collection That Explores What It Means to Be Human
- Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787
- New Portable Toilet Drain Adapter Eliminates Manual Waste Tank Emptying
- Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
- Night Shade Introduces Smart Privacy Protection for Modern Devices
- Innovative Ear Muff Hat Combines Warmth and Convenience in One Winter Accessory
- Danholm Collection Announces Sale of 16689 Broadwater Ave in Winter Garden, Highlighting Strong Performance in Twinwaters Community
- New Repositionable Handheld Easel Offers Artists Greater Freedom and Flexibility